Progyny/$PGNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Ticker
$PGNY
Sector
Primary listing
Employees
678
Headquarters
Website
Progyny Metrics
BasicAdvanced
$2B
40.92
$0.57
1.31
-
Price and volume
Market cap
$2B
Beta
1.31
52-week high
$26.76
52-week low
$13.39
Average daily volume
1.1M
Financial strength
Current ratio
2.394
Quick ratio
2.344
Long term debt to equity
5.565
Total debt to equity
6.185
Profitability
EBITDA (TTM)
76.669
Gross margin (TTM)
21.99%
Net profit margin (TTM)
4.33%
Operating margin (TTM)
6.03%
Effective tax rate (TTM)
39.81%
Revenue per employee (TTM)
$1,790,000
Management effectiveness
Return on assets (TTM)
5.99%
Return on equity (TTM)
10.11%
Valuation
Price to earnings (TTM)
40.917
Price to revenue (TTM)
1.695
Price to book
4.22
Price to tangible book (TTM)
4.47
Price to free cash flow (TTM)
10.506
Free cash flow yield (TTM)
9.52%
Free cash flow per share (TTM)
2.206
Growth
Revenue change (TTM)
9.47%
Earnings per share change (TTM)
-7.16%
3-year revenue growth (CAGR)
30.12%
3-year earnings per share growth (CAGR)
0.36%
What the Analysts think about Progyny
Analyst ratings (Buy, Hold, Sell) for Progyny stock.
Bulls say / Bears say
Progyny reported a 16.5% year-over-year increase in Q1 2025 revenue to $324 million, driven by growth in fertility and pharmacy benefits. (stocktitan.net)
The company expanded its client base to 532, up from 451 in Q1 2024, indicating strong market demand for its services. (stocktitan.net)
Progyny secured a $200 million revolving credit facility to enhance financial flexibility, supporting future growth initiatives. (gurufocus.com)
Net income in Q1 2025 decreased by 11% year-over-year to $15.1 million, despite revenue growth. (panabee.com)
Operating expenses increased by 18% year-over-year in Q1 2025, outpacing revenue growth and impacting profitability. (panabee.com)
The company lost a major client for 2025, which may negatively affect future revenue and client retention. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Progyny Financial Performance
Revenues and expenses
Progyny Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Progyny stock?
Progyny (PGNY) has a market cap of $2B as of August 06, 2025.
What is the P/E ratio for Progyny stock?
The price to earnings (P/E) ratio for Progyny (PGNY) stock is 40.92 as of August 06, 2025.
Does Progyny stock pay dividends?
No, Progyny (PGNY) stock does not pay dividends to its shareholders as of August 06, 2025.
When is the next Progyny dividend payment date?
Progyny (PGNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Progyny?
Progyny (PGNY) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.